Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Tumor Lysis Syndrome 2Lymphoma 1Leukemia 1Inflammation 1Hyperuricemia 1Hematologic Neoplasms 1Gout 1Cardiovascular Diseases 1Arthritis 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Febuxostat × Clear all
NCT03605212 2021-06-03

FLORET

Menarini Group

Phase 1/2 Terminated
30 enrolled 14 charts
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed
196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡